Tabi Anika Leslie

Suggest Changes
Learn More
BACKGROUND Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamines. Ciclosporin is an established but(More)
  • 1